3x1i - Revision history

OCA at 10:41, 31 August 2022

2022-08-31T10:41:23Z

←Older revision		Revision as of 10:41, 31 August 2022
Line 1:		Line 1:

	==hPPARgamma Ligand binding domain in complex with 6-oxo-tetracosahexaenoic acid==		==hPPARgamma Ligand binding domain in complex with 6-oxo-tetracosahexaenoic acid==
-	<StructureSection load='3x1i' size='340' side='right'caption='[[3x1i]]~~, [[Resolution\|resolution]] 2.40Å~~' scene=''>	+	<StructureSection load='3x1i' size='340' side='right'caption='[[3x1i]]' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>~~[[3x1i]] is a 2 chain structure.~~ Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3X1I OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3X1I FirstGlance]. <br>	+	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3X1I OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3X1I FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=66B:(8E,12Z,15Z,18Z,21Z)-6-OXOTETRACOSA-8,12,15,18,21-PENTAENOIC+ACID'>66B</scene></td></tr>	+	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3x1i FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3x1i OCA], [https://pdbe.org/3x1i PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3x1i RCSB], [https://www.ebi.ac.uk/pdbsum/3x1i PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3x1i ProSAT]</span></td></tr>
-	~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[3x1h\|3x1h]]</div></td></tr>~~	+
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3x1i FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3x1i OCA], [https://pdbe.org/3x1i PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3x1i RCSB], [https://www.ebi.ac.uk/pdbsum/3x1i PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3x1i ProSAT]</span></td></tr>	+
	</table>		</table>
-	== Disease ==
-	[[https://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN]] Note=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer. Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:[https://omim.org/entry/601665 601665]]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.<ref>PMID:9753710</ref> Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:[https://omim.org/entry/604367 604367]]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.<ref>PMID:12453919</ref> <ref>PMID:11788685</ref> Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:[https://omim.org/entry/137800 137800]]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.
-	== Function ==
-	[[https://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN]] Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses.<ref>PMID:9065481</ref> <ref>PMID:16150867</ref> <ref>PMID:20829347</ref>
-	<div style="background-color:#fffaf0;">
-	== Publication Abstract from PubMed ==
-	Covalent modification of proteins is important for normal cellular regulation. Here, we report on the covalent modification of peroxisome proliferator-activated receptor gamma (PPARgamma), an important drug target, by oxo-fatty acids. In this study, ESI mass spectroscopy showed that the reactivities of oxo-fatty acids with PPARgamma are different from one another and that these behaviors are related to the structure of the fatty acids. X-ray crystallography showed that three oxo-fatty acids all bound to the same residue of PPARgamma (Cys285), but displayed different hydrogen bonding modes. Moreover, fatty acids formed covalent bonds with both PPARgamma moieties in the homodimer, one in an active conformation and the other in an alternative conformation. These two conformations may explain why covalently bound fatty acids show partial rather than full agonist activity.
-
-	Characterization of Covalent Bond Formation between PPARgamma and Oxo-Fatty Acids.,Egawa D, Itoh T, Yamamoto K Bioconjug Chem. 2015 Mar 26. PMID:25785518<ref>PMID:25785518</ref>
-
-	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	</div>
-	<div class="pdbe-citations 3x1i" style="background-color:#fffaf0;"></div>

	==See Also==		==See Also==
	*[[Peroxisome proliferator-activated receptor 3D structures\|Peroxisome proliferator-activated receptor 3D structures]]		*[[Peroxisome proliferator-activated receptor 3D structures\|Peroxisome proliferator-activated receptor 3D structures]]
-	== References ==
-	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Egawa, D]]	+	[[Category: Egawa D]]
-	[[Category: Itoh, T]]	+	[[Category: Itoh T]]
-	[[Category: Yamamoto, K]]	+	[[Category: Yamamoto K]]
-	~~[[Category: Diabetes mellitus]]~~	+
-	~~[[Category: Dna-binding]]~~	+
-	~~[[Category: Ligand binding domain]]~~	+
-	~~[[Category: Nuclear receptor]]~~	+
-	~~[[Category: Obesity]]~~	+
-	~~[[Category: Transcription]]~~	+
-	~~[[Category: Transcription regulation]]~~	+
-	~~[[Category: Zinc-finger~~]]	+

OCA at 05:01, 25 August 2022

2022-08-25T05:01:16Z

←Older revision		Revision as of 05:01, 25 August 2022
Line 3:		Line 3:
	<StructureSection load='3x1i' size='340' side='right'caption='[[3x1i]], [[Resolution\|resolution]] 2.40Å' scene=''>		<StructureSection load='3x1i' size='340' side='right'caption='[[3x1i]], [[Resolution\|resolution]] 2.40Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[3x1i]] is a 2 chain structure ~~with sequence from [https://en.wikipedia.org/wiki/Human Human]~~. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3X1I OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3X1I FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[3x1i]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3X1I OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3X1I FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=66B:(8E,12Z,15Z,18Z,21Z)-6-OXOTETRACOSA-8,12,15,18,21-PENTAENOIC+ACID'>66B</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=66B:(8E,12Z,15Z,18Z,21Z)-6-OXOTETRACOSA-8,12,15,18,21-PENTAENOIC+ACID'>66B</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[3x1h\|3x1h]]</div></td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[3x1h\|3x1h]]</div></td></tr>
-	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">PPARG, NR1C3 ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3x1i FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3x1i OCA], [https://pdbe.org/3x1i PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3x1i RCSB], [https://www.ebi.ac.uk/pdbsum/3x1i PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3x1i ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3x1i FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3x1i OCA], [https://pdbe.org/3x1i PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3x1i RCSB], [https://www.ebi.ac.uk/pdbsum/3x1i PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3x1i ProSAT]</span></td></tr>
	</table>		</table>
Line 29:		Line 28:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: Human]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
	[[Category: Egawa, D]]		[[Category: Egawa, D]]

OCA at 05:38, 10 August 2022

2022-08-10T05:38:34Z

←Older revision		Revision as of 05:38, 10 August 2022
Line 1:		Line 1:

	==hPPARgamma Ligand binding domain in complex with 6-oxo-tetracosahexaenoic acid==		==hPPARgamma Ligand binding domain in complex with 6-oxo-tetracosahexaenoic acid==
-	<StructureSection load='3x1i' size='340' side='right' caption='[[3x1i]], [[Resolution\|resolution]] 2.40Å' scene=''>	+	<StructureSection load='3x1i' size='340' side='right'caption='[[3x1i]], [[Resolution\|resolution]] 2.40Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[3x1i]] is a 2 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3X1I OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=3X1I FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[3x1i]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3X1I OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3X1I FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=66B:(8E,12Z,15Z,18Z,21Z)-6-OXOTETRACOSA-8,12,15,18,21-PENTAENOIC+ACID'>66B</scene></td></tr>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=66B:(8E,12Z,15Z,18Z,21Z)-6-OXOTETRACOSA-8,12,15,18,21-PENTAENOIC+ACID'>66B</scene></td></tr>
-	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[3x1h\|3x1h]]</td></tr>	+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[3x1h\|3x1h]]</div></td></tr>
-	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">PPARG, NR1C3 ([~~http~~://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>	+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">PPARG, NR1C3 ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=3x1i FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3x1i OCA], [~~http~~://pdbe.org/3x1i PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=3x1i RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/3x1i PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=3x1i ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3x1i FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3x1i OCA], [https://pdbe.org/3x1i PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3x1i RCSB], [https://www.ebi.ac.uk/pdbsum/3x1i PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3x1i ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
-	[[~~http~~://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN]] Note=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer. Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:[~~http~~://omim.org/entry/601665 601665]]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.<ref>PMID:9753710</ref> Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:[~~http~~://omim.org/entry/604367 604367]]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.<ref>PMID:12453919</ref> <ref>PMID:11788685</ref> Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:[~~http~~://omim.org/entry/137800 137800]]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.	+	[[https://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN]] Note=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer. Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:[https://omim.org/entry/601665 601665]]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.<ref>PMID:9753710</ref> Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:[https://omim.org/entry/604367 604367]]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.<ref>PMID:12453919</ref> <ref>PMID:11788685</ref> Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:[https://omim.org/entry/137800 137800]]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.
	== Function ==		== Function ==
-	[[~~http~~://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN]] Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses.<ref>PMID:9065481</ref> <ref>PMID:16150867</ref> <ref>PMID:20829347</ref>	+	[[https://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN]] Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses.<ref>PMID:9065481</ref> <ref>PMID:16150867</ref> <ref>PMID:20829347</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 22:		Line 22:
	</div>		</div>
	<div class="pdbe-citations 3x1i" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 3x1i" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Peroxisome proliferator-activated receptor 3D structures\|Peroxisome proliferator-activated receptor 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
Line 27:		Line 30:
	</StructureSection>		</StructureSection>
	[[Category: Human]]		[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Egawa, D]]		[[Category: Egawa, D]]
	[[Category: Itoh, T]]		[[Category: Itoh, T]]

OCA at 08:12, 22 November 2017

2017-11-22T08:12:58Z

←Older revision		Revision as of 08:12, 22 November 2017
Line 3:		Line 3:
	<StructureSection load='3x1i' size='340' side='right' caption='[[3x1i]], [[Resolution\|resolution]] 2.40Å' scene=''>		<StructureSection load='3x1i' size='340' side='right' caption='[[3x1i]], [[Resolution\|resolution]] 2.40Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[3x1i]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3X1I OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3X1I FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[3x1i]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3X1I OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3X1I FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=66B:(8E,12Z,15Z,18Z,21Z)-6-OXOTETRACOSA-8,12,15,18,21-PENTAENOIC+ACID'>66B</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=66B:(8E,12Z,15Z,18Z,21Z)-6-OXOTETRACOSA-8,12,15,18,21-PENTAENOIC+ACID'>66B</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[3x1h\|3x1h]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[3x1h\|3x1h]]</td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">PPARG, NR1C3 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3x1i FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3x1i OCA], [http://pdbe.org/3x1i PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=3x1i RCSB], [http://www.ebi.ac.uk/pdbsum/3x1i PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=3x1i ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3x1i FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3x1i OCA], [http://pdbe.org/3x1i PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=3x1i RCSB], [http://www.ebi.ac.uk/pdbsum/3x1i PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=3x1i ProSAT]</span></td></tr>
	</table>		</table>
Line 25:		Line 26:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
	[[Category: Egawa, D]]		[[Category: Egawa, D]]
	[[Category: Itoh, T]]		[[Category: Itoh, T]]

OCA at 17:15, 18 January 2017

2017-01-18T17:15:10Z

←Older revision		Revision as of 17:15, 18 January 2017
Line 1:		Line 1:
		+
	==hPPARgamma Ligand binding domain in complex with 6-oxo-tetracosahexaenoic acid==		==hPPARgamma Ligand binding domain in complex with 6-oxo-tetracosahexaenoic acid==
	<StructureSection load='3x1i' size='340' side='right' caption='[[3x1i]], [[Resolution\|resolution]] 2.40Å' scene=''>		<StructureSection load='3x1i' size='340' side='right' caption='[[3x1i]], [[Resolution\|resolution]] 2.40Å' scene=''>
Line 5:		Line 6:
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=66B:(8E,12Z,15Z,18Z,21Z)-6-OXOTETRACOSA-8,12,15,18,21-PENTAENOIC+ACID'>66B</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=66B:(8E,12Z,15Z,18Z,21Z)-6-OXOTETRACOSA-8,12,15,18,21-PENTAENOIC+ACID'>66B</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[3x1h\|3x1h]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[3x1h\|3x1h]]</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3x1i FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3x1i OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3x1i RCSB], [http://www.ebi.ac.uk/pdbsum/3x1i PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3x1i FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3x1i OCA], [http://pdbe.org/3x1i PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=3x1i RCSB], [http://www.ebi.ac.uk/pdbsum/3x1i PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=3x1i ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 19:		Line 20:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
		+	<div class="pdbe-citations 3x1i" style="background-color:#fffaf0;"></div>
	== References ==		== References ==
	<references/>		<references/>

OCA at 11:01, 8 April 2015

2015-04-08T11:01:31Z

←Older revision		Revision as of 11:01, 8 April 2015
Line 1:		Line 1:
-	'''~~Unreleased~~ structure'''	+	==hPPARgamma Ligand binding domain in complex with 6-oxo-tetracosahexaenoic acid==
		+	<StructureSection load='3x1i' size='340' side='right' caption='[[3x1i]], [[Resolution\|resolution]] 2.40Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[3x1i]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3X1I OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3X1I FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=66B:(8E,12Z,15Z,18Z,21Z)-6-OXOTETRACOSA-8,12,15,18,21-PENTAENOIC+ACID'>66B</scene></td></tr>
		+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[3x1h\|3x1h]]</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3x1i FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3x1i OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3x1i RCSB], [http://www.ebi.ac.uk/pdbsum/3x1i PDBsum]</span></td></tr>
		+	</table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN]] Note=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer. Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:[http://omim.org/entry/601665 601665]]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.<ref>PMID:9753710</ref> Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:[http://omim.org/entry/604367 604367]]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.<ref>PMID:12453919</ref> <ref>PMID:11788685</ref> Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:[http://omim.org/entry/137800 137800]]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/PPARG_HUMAN PPARG_HUMAN]] Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses.<ref>PMID:9065481</ref> <ref>PMID:16150867</ref> <ref>PMID:20829347</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Covalent modification of proteins is important for normal cellular regulation. Here, we report on the covalent modification of peroxisome proliferator-activated receptor gamma (PPARgamma), an important drug target, by oxo-fatty acids. In this study, ESI mass spectroscopy showed that the reactivities of oxo-fatty acids with PPARgamma are different from one another and that these behaviors are related to the structure of the fatty acids. X-ray crystallography showed that three oxo-fatty acids all bound to the same residue of PPARgamma (Cys285), but displayed different hydrogen bonding modes. Moreover, fatty acids formed covalent bonds with both PPARgamma moieties in the homodimer, one in an active conformation and the other in an alternative conformation. These two conformations may explain why covalently bound fatty acids show partial rather than full agonist activity.

-	~~The entry 3x1i is ON HOLD~~	+	Characterization of Covalent Bond Formation between PPARgamma and Oxo-Fatty Acids.,Egawa D, Itoh T, Yamamoto K Bioconjug Chem. 2015 Mar 26. PMID:25785518<ref>PMID:25785518</ref>

-	~~Authors: Egawa~~, D.~~, Itoh, T~~.~~, Yamamoto, K~~.	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-		+	</div>
-	~~Description: hPPARgamma Ligand binding domain in complex with 6-oxo-tetracosahexaenoic acid~~	+	== References ==
-	~~[[Category: Unreleased Structures]]~~	+	<references/>
-	~~[[Category: Yamamoto, K]]~~	+	__TOC__
		+	</StructureSection>
	[[Category: Egawa, D]]		[[Category: Egawa, D]]
	[[Category: Itoh, T]]		[[Category: Itoh, T]]
		+	[[Category: Yamamoto, K]]
		+	[[Category: Diabetes mellitus]]
		+	[[Category: Dna-binding]]
		+	[[Category: Ligand binding domain]]
		+	[[Category: Nuclear receptor]]
		+	[[Category: Obesity]]
		+	[[Category: Transcription]]
		+	[[Category: Transcription regulation]]
		+	[[Category: Zinc-finger]]

OCA at 13:14, 24 December 2014

2014-12-24T13:14:19Z

←Older revision		Revision as of 13:14, 24 December 2014
Line 6:		Line 6:

	Description: hPPARgamma Ligand binding domain in complex with 6-oxo-tetracosahexaenoic acid		Description: hPPARgamma Ligand binding domain in complex with 6-oxo-tetracosahexaenoic acid
		+	[[Category: Unreleased Structures]]
		+	[[Category: Yamamoto, K]]
		+	[[Category: Egawa, D]]
		+	[[Category: Itoh, T]]

OCA: Protected "3x1i" [edit=sysop:move=sysop]

2014-11-26T06:24:03Z

Protected "3x1i" [edit=sysop:move=sysop]

←Older revision

Revision as of 06:24, 26 November 2014

OCA: New page: '''Unreleased structure''' The entry 3x1i is ON HOLD Authors: Egawa, D., Itoh, T., Yamamoto, K. Description: hPPARgamma Ligand binding domain in complex with 6-oxo-tetracosahexaenoic a...

2014-11-26T06:24:02Z

New page: '''Unreleased structure''' The entry 3x1i is ON HOLD Authors: Egawa, D., Itoh, T., Yamamoto, K. Description: hPPARgamma Ligand binding domain in complex with 6-oxo-tetracosahexaenoic a...

New page

'''Unreleased structure'''

The entry 3x1i is ON HOLD

Authors: Egawa, D., Itoh, T., Yamamoto, K.

Description: hPPARgamma Ligand binding domain in complex with 6-oxo-tetracosahexaenoic acid